Leiden, The Netherlands and Oslo, Norway, September, 1st 2020 – DCprime, the front-runner in the field of relapse vaccines, and PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation, today announced an extensive research collaboration. Within the collaboration, DCprime and PCI Biotech will combine their know-how and technology platforms to pursue the development of novel cancer vaccination concepts based on tumour-independent antigens (TIAs). The collaboration builds on preclinical proof-of-concept results previously presented by DCprime at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2019 and on PCI Biotech fimaVACC and fimaNAC technologies.
The partnership is governed by a research collaboration agreement, under which the collaborators will perform an extensive evaluation of technology compatibility and synergy based on preclinical studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for further development and partnership.
Commenting on the announcement, Erik Manting, CEO of DCprime said: “We continue to innovate the cancer vaccine space and look forward to working closely with PCI Biotech on a ground-breaking off-the shelf vaccination concept for solid tumours addressing the huge need for novel antigen targets in oncology. Having access to PCI Biotech’s intracellular antigen delivery platforms and expertise will accelerate the development of therapeutic approaches based on the unique and novel principle we developed using tumour-independent antigens. This complements DCprime’s existing pipeline of relapse vaccines progressing through clinical trials in haematological malignancies.”
PCI Biotech’s CEO, Per Walday, added: “We are very pleased to collaborate with DCprime. This collaboration could reinforce the fimaVACC positive results obtained during a phase I study presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2019, and the preclinical promising results obtained with fimaNAC, the PCI-mediated intracellular delivery of various types of “naked” mRNA molecules. Combining the complementary technologies of DCprime and PCI Biotech could lead to entirely new therapeutic clinical applications.”
About DCprime
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. Our lead product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. We are pursuing similar vaccination approaches for solid tumours. We believe relapse vaccines will improve survival by putting the patient’s immune system back in control. For more information, please visit: https://dcprime.com/
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform, for intracellular delivery. PCI induces triggered endosomal release that enables drugs to reach intracellular therapeutic targets. Currently, PCI Biotech is working on three programs: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAC (nucleic acid therapeutics delivery). For more information, please visit: www.pcibiotech.com
Contact Information:
DCprime BV
Dr. Erik Manting, CEO
Phone: +31 713322627
Email: e.manting@dcprime.com
Media Contact:
Mario Brkulj or Nicholas Chang
MacDougall
Phone: +49 175 5711562 or +1 781 235 3060
E-Mail: dcprime@macbiocom.com
PCI Biotech Holding ASA
Per Walday, CEO
Mobile: +47 917 93 429
Email: pw@pcibiotech.no
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.